

# Antonio C Wolff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8968737/publications.pdf>

Version: 2024-02-01

314  
papers

41,248  
citations

5558

82  
h-index

2500

196  
g-index

321  
all docs

321  
docs citations

321  
times ranked

34156  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013.	0.8	3,276
2	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 26, 118-145.	0.8	3,139
3	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2784-2795.	0.8	2,667
4	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7703-7720.	0.8	1,674
5	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2006, 24, 3187-3205.	0.8	1,530
6	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	0.8	1,362
7	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 18-43.	1.2	1,359
8	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. <i>Journal of Clinical Oncology</i> , 2014, 32, 2959-2966.	0.8	1,080
9	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 241-256.	1.2	961
10	Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1663-1671.	13.9	855
11	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, e48-e72.	1.2	855
12	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004. <i>Journal of Clinical Oncology</i> , 2005, 23, 619-629.	0.8	810
13	Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2754.	3.8	724
14	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 907-922.	1.2	697
15	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	0.8	673
16	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	1.2	644
17	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
18	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 961-965.	0.8	517

#	ARTICLE	IF	CITATIONS
19	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
20	Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 2055-2065.	13.9	504
21	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Journal of Oncology Practice</i> , 2010, 6, 195-197.	2.5	494
22	American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. <i>Journal of Clinical Oncology</i> , 2006, 24, 5091-5097.	0.8	478
23	Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2008, 26, 1810-1816.	0.8	475
24	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	0.8	413
25	Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 122-192.	2.3	389
26	Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 40-46.	0.8	365
27	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2643-2650.	3.2	341
28	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	0.8	315
29	Detection of Tumor <i>PIK3CA</i> Status in Metastatic Breast Cancer Using Peripheral Blood. <i>Clinical Cancer Research</i> , 2012, 18, 3462-3469.	3.2	296
30	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
31	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temeosolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 195-202.	0.8	252
32	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
33	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2838-2847.	0.8	241
34	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
35	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. <i>Journal of Clinical Oncology</i> , 2009, 27, 5911-5918.	0.8	217
36	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	1.2	205

#	ARTICLE	IF	CITATIONS
37	Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. <i>Journal of General Internal Medicine</i> , 2009, 24, 459-466.	1.3	196
38	Treatment of HER2-positive breast cancer. <i>Breast</i> , 2014, 23, 128-136.	0.9	191
39	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 1956-1964.	0.8	189
40	Past, Present, and Future Challenges in Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 1979-1986.	0.8	180
41	Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. <i>Cancer Research</i> , 2011, 71, 6195-6207.	0.4	179
42	Obesity at diagnosis is associated with inferior outcomes in hormone receptor–positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	2.0	174
43	Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive <sup>23</sup> Na MRI. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 151-160.	1.1	171
44	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
45	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	0.8	167
46	Breast Cancer Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 542-590.	2.3	159
47	Prevention, Screening, and Surveillance Care for Breast Cancer Survivors Compared With Controls: Changes from 1998 to 2002. <i>Journal of Clinical Oncology</i> , 2009, 27, 1054-1061.	0.8	152
48	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	3.4	151
49	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.4	149
50	Pharmacogenetic Pathway Analysis of Docetaxel Elimination. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 155-163.	2.3	148
51	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
52	Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese. <i>Journal of Clinical Oncology</i> , 2007, 25, 4707-4713.	0.8	141
53	Postoperative Mortality in Cancer Patients With Preexisting Diabetes. <i>Diabetes Care</i> , 2010, 33, 931-939.	4.3	140
54	Long term side effects of adjuvant chemotherapy in patients with early breast cancer. <i>Breast</i> , 2015, 24, S149-S153.	0.9	140

#	ARTICLE	IF	CITATIONS
55	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	0.8	139
56	Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. <i>Annals of Internal Medicine</i> , 2008, 148, 358.	2.0	135
57	Breast Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 753-761.	2.3	134
58	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	0.8	134
59	Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study. <i>Journal of General Internal Medicine</i> , 2009, 24, 469-474.	1.3	132
60	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	0.8	131
61	Invasive Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 136-222.	2.3	124
62	Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1839-1851.	1.1	120
63	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. <i>Journal of Clinical Oncology</i> , 2010, 28, 2418-2422.	0.8	116
64	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	0.8	116
65	The Role of Informatics in Promoting Patient-Centered Care. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 211-218.	1.0	115
66	Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel. <i>Clinical Cancer Research</i> , 2004, 10, 1976-1983.	3.2	112
67	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	0.8	112
68	Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice. <i>Psycho-Oncology</i> , 2013, 22, 895-901.	1.0	111
69	HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 437-441.	2.5	111
70	NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-21.	2.3	110
71	Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, e458-e458.	0.8	110
72	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758.	0.8	110

#	ARTICLE	IF	CITATIONS
73	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacididine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	3.2	106
74	Older Adultsâ€™ Views and Communication Preferences About Cancer Screening Cessation. <i>JAMA Internal Medicine</i> , 2017, 177, 1121.	2.6	100
75	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
76	The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 670-678.	2.3	96
77	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348.	0.8	94
78	Metastatic Breast Cancer, Version 1.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 821-829.	2.3	94
79	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
80	Tumor targeting by conjugation of DHA to paclitaxel. <i>Journal of Controlled Release</i> , 2001, 74, 233-236.	4.8	90
81	Race and Hormone Receptorâ€“Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 406-414.	3.0	89
82	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
83	Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 3828-3834.	0.8	85
84	Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. <i>Supportive Care in Cancer</i> , 2007, 15, 1075-1085.	1.0	85
85	Primary Systemic Therapy in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1558-1569.	0.8	84
86	Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3051-3057.	0.8	83
87	A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5922-8.	3.2	79
88	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	3.2	78
89	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	0.8	78
90	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSFâ€“Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	1.6	77

#	ARTICLE	IF	CITATIONS
91	A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 1971-1975.	3.2	76
92	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apolisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
93	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
94	NCCN Invasive Breast Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 246.	2.3	76
95	Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3117-3125.	0.8	75
96	Quality of Care for Comorbid Conditions During the Transition to Survivorship: Differences Between Cancer Survivors and Noncancer Controls. <i>Journal of Clinical Oncology</i> , 2013, 31, 1140-1148.	0.8	74
97	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
98	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
99	Monitoring of neoadjuvant chemotherapy using multiparametric, <sup>23</sup> Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 119-126.	1.1	69
100	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	0.8	68
101	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
102	Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 920-927.	1.3	67
103	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693.	0.8	66
104	Predicting Cancer Therapy-Induced Cardiotoxicity. <i>Drug Safety</i> , 2002, 25, 301-311.	1.4	65
105	Chemotherapy-related amenorrhea after adjuvant paclitaxel+trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	1.1	65
106	HER2 testing in breast cancer: NCCN Task Force report and recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4 Suppl 3, S1-22; quiz S23-4.	2.3	65
107	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 907-914.	1.1	62
108	Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. <i>European Journal of Cancer</i> , 2004, 40, 1170-1178.	1.3	61

#	ARTICLE	IF	CITATIONS
109	TBCRC 008: Early Change in <sup>18</sup> F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	2.8	61
110	Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. <i>Clinical Cancer Research</i> , 2003, 9, 3589-97.	3.2	60
111	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	1.1	59
112	Racial disparities in the rate of cardiotoxicity of HER2 <sup>+</sup> targeted therapies among women with early breast cancer. <i>Cancer</i> , 2018, 124, 1904-1911.	2.0	59
113	Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 58-64.	2.0	58
114	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 915-924.	1.1	57
115	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	3.2	57
116	Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 2017, 1-19.	1.5	57
117	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	0.8	56
118	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor <sup>+</sup> Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	0.8	54
119	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4390-4397.	0.8	51
120	A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence <sup>+</sup> Score Assay. <i>Clinical Breast Cancer</i> , 2015, 15, 467-472.	1.1	50
121	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	3.2	50
122	Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( <sup>23</sup> Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. <i>Academic Radiology</i> , 2010, 17, 1477-1485.	1.3	49
123	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 <sup>+</sup> Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
124	Symptoms, supportive care needs, and function in cancer patients: how are they related?. <i>Quality of Life Research</i> , 2008, 17, 665-677.	1.5	48
125	Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease. <i>Oncologist</i> , 2002, 7, 239-245.	1.9	47
126	Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination. <i>Journal of Cancer Survivorship</i> , 2015, 9, 641-649.	1.5	47



#	ARTICLE	IF	CITATIONS
127	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. <i>Obesity</i> , 2020, 28, 1678-1686.	1.5	47
128	Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. <i>Journal of Clinical Oncology</i> , 2007, 25, 1677-1682.	0.8	45
129	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy. <i>Cancer</i> , 2010, 116, 4168-4177.	2.0	44
130	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	1.4	44
131	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 511-511.	0.8	43
132	Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. <i>Quality of Life Research</i> , 2010, 19, 837-845.	1.5	42
133	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , 2016, 34, 699-705.	0.8	42
134	Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. <i>Clinical Cancer Research</i> , 2003, 9, 151-9.	3.2	42
135	Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 543-550.	0.8	41
136	A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1006-1006.	0.8	41
137	Improving an electronic system for measuring PROs in routine oncology practice. <i>Journal of Cancer Survivorship</i> , 2016, 10, 573-582.	1.5	40
138	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 821-827.	3.2	40
139	Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1615-1622.	0.8	39
140	A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-“Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. <i>Human Gene Therapy</i> , 2004, 15, 313-337.	1.4	39
141	Concordance of cancer patients’™ function, symptoms, and supportive care needs. <i>Quality of Life Research</i> , 2009, 18, 991-998.	1.5	39
142	Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab. <i>Stem Cells Translational Medicine</i> , 2012, 1, 289-297.	1.6	36
143	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	0.8	36
144	It’s™s who you know: patient-sharing, quality, and costs of cancer survivorship care. <i>Journal of Cancer Survivorship</i> , 2014, 8, 156-166.	1.5	35

#	ARTICLE	IF	CITATIONS
145	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
146	Breast Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 238.	2.3	34
147	The Adjuvant Treatment of HER2-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 230-239.	1.3	32
148	Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 689-702.	1.1	32
149	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1BA4-1BA4.	0.8	32
150	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1005-1005.	0.8	32
151	NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, S-1-S-26.	2.3	32
152	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1302-1304.	0.8	31
153	Older Adultsâ€™ Preferences for Discussing Long-Term Life Expectancy: Results From a National Survey. <i>Annals of Family Medicine</i> , 2018, 16, 530-537.	0.9	31
154	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	3.2	31
155	Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. <i>Cancer</i> , 2018, 124, 899-906.	2.0	30
156	Local/regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
157	Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. <i>Oncologist</i> , 2013, 18, 134-140.	1.9	29
158	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.	1.3	29
159	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	0.8	29
160	Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1852-1860.	1.0	28
161	Quality of End-of-Life Care for Patients with Advanced Cancer in an Academic Medical Center. <i>Journal of Palliative Medicine</i> , 2011, 14, 451-457.	0.6	27
162	Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 111-120.	1.1	26

#	ARTICLE	IF	CITATIONS
163	Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults. <i>JAMA Oncology</i> , 2018, 4, 1126.	3.4	26
164	CDK4 and CDK6 Inhibition in Breast Cancer â€” A New Standard. <i>New England Journal of Medicine</i> , 2016, 375, 1993-1994.	13.9	25
165	Enhancing Therapeutic Decision Making When Options Abound: Toxicities Matter. <i>Journal of Clinical Oncology</i> , 2014, 32, 1990-1993.	0.8	24
166	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
167	The impact of sharing results of a randomized breast cancer clinical trial with study participants. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 123-129.	1.1	23
168	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. <i>Cancer Prevention Research</i> , 2011, 4, 1993-2001.	0.7	23
169	A randomized intervention involving family to improve communication in breast cancer care. <i>Npj Breast Cancer</i> , 2021, 7, 14.	2.3	23
170	The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3024-3034.	3.2	22
171	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	0.8	22
172	Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (Tâ†L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 502-502.	0.8	22
173	Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support. <i>Journal of Clinical Oncology</i> , 2006, 24, 2392-2394.	0.8	21
174	Luteinizing Hormone-Releasing Hormone Agonists in Premenopausal Hormone Receptorâ€”Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 455-464.	1.1	21
175	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	3.2	21
176	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
177	Troponins for predicting cardiotoxicity from cancer therapy. <i>Lancet, The</i> , 2000, 356, 1947-1948.	6.3	20
178	Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. <i>Oncologist</i> , 2003, 8, 25-30.	1.9	20
179	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. <i>PLoS ONE</i> , 2014, 9, e105545.	1.1	20
180	Estrogen Receptor: A Never Ending Story?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2955-2958.	0.8	19

#	ARTICLE	IF	CITATIONS
181	Evaluating information prescriptions in two clinical environments. <i>Journal of the Medical Library Association: JMLA</i> , 2011, 99, 237-246.	0.6	19
182	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	1.1	19
183	African American Women Who Receive Primary Anthracycline- and Taxane-Based Chemotherapy for Triple-Negative Breast Cancer Suffer Worse Outcomes Compared With White Women. <i>Journal of Clinical Oncology</i> , 2009, 27, e35-e37.	0.8	18
184	Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq0 0 rgBT/Overlock	1.0	18
185	Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay. <i>Cancers</i> , 2020, 12, 2772.	1.7	18
186	Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1044-1044.	0.8	18
187	With maturity comes confidence: EBCTCG tamoxifen update. <i>Lancet, The</i> , 2011, 378, 747-749.	6.3	17
188	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 121-129.	1.1	17
189	Sharing in care: engaging care partners in the care and communication of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 127-136.	1.1	17
190	Demographic, health, and attitudinal factors predictive of cancer screening decisions in older adults. <i>Preventive Medicine Reports</i> , 2019, 13, 244-248.	0.8	17
191	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	3.6	17
192	ERBB2-Low Breast Cancer—Is It a Fact or Fiction, and Do We Have the Right Assay?. <i>JAMA Oncology</i> , 2022, 8, 610.	3.4	17
193	Re: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. <i>Journal of the National Cancer Institute</i> , 2012, 104, 957-958.	3.0	16
194	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 135-143.	1.1	16
195	Patient perspectives on chemotherapy de-escalation in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 3288-3298.	1.3	16
196	Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2816-2822.	0.8	15
197	Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 40-45.	1.1	15
198	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 153-162.	1.1	15

#	ARTICLE	IF	CITATIONS
199	Older Adults™ Preferences for When and How to Discuss Life Expectancy in Primary Care. <i>Journal of the American Board of Family Medicine</i> , 2017, 30, 813-815.	0.8	15
200	Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
201	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 3.	2.3	15
202	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 16.	2.3	15
203	The androgen receptor in breast cancer: learning from the past. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 619-621.	1.1	14
204	Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. <i>Cancer Biology and Therapy</i> , 2011, 12, 808-817.	1.5	14
205	Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 465-474.	1.1	14
206	Reply to G. Sauter et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e153-e154.	0.8	13
207	A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. <i>Human Pathology</i> , 2014, 45, 880-883.	1.1	13
208	Evolving Role of the Estrogen Receptor as a Predictive Biomarker: <i>ESR1</i> Mutational Status and Endocrine Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2950-2952.	0.8	13
209	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
210	Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endocrine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. , 2015, . .		13
211	Distribution of GABA-immunoreactive nerve fibers and cells in the cervical and thoracic paravertebral sympathetic trunk of adult rat: Evidence for an ascending feed-forward inhibition system. <i>Journal of Comparative Neurology</i> , 1993, 334, 281-293.	0.9	12
212	Single-Agent Topotecan as First-Line Chemotherapy in Women with Metastatic Breast Cancer: Final Results of Eastern Cooperative Oncology Group Trial E8193. <i>Clinical Breast Cancer</i> , 2005, 6, 334-339.	1.1	12
213	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	0.8	12
214	Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 225-230.	0.8	12
215	Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1041-1043.	3.0	11
216	The role of ovarian ablation in the adjuvant therapy of breast cancer. <i>Current Oncology Reports</i> , 2008, 10, 27-37.	1.8	11

#	ARTICLE	IF	CITATIONS
217	Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 40-46.	0.9	11
218	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions. JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
219	How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment. <i>Medical Decision Making</i> , 2019, 39, 621-631.	1.2	11
220	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
221	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 797-804.	2.3	11
222	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. <i>Npj Breast Cancer</i> , 2022, 8, 53.	2.3	11
223	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. <i>Clinical Cancer Research</i> , 2005, 11, 8503-8511.	3.2	10
224	Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program. <i>Cancer</i> , 2013, 119, 158-163.	2.0	10
225	Breast cancer survivorship care beyond local and systemic therapy. <i>Breast</i> , 2019, 48, S103-S109.	0.9	10
226	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	0.8	10
227	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	2.3	9
228	Clinical Practice Guidelines in Oncology: Translating Evidence Into Practice (and back). <i>Journal of Oncology Practice</i> , 2005, 1, 160-161.	2.5	8
229	Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1243-1253.	1.1	8
230	Breast Cancer: Noninvasive and Special Situations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1182-1207.	2.3	8
231	Coordination of Care in Breast Cancer Survivors: An Overview. <i>The Journal of Supportive Oncology</i> , 2011, 9, 210-215.	2.3	8
232	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab017.	1.4	8
233	Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) and entinostat (MS-275) in patients with triple-negative advanced breast cancer.. <i>Cancer Research</i> , 2013, 73, 4666-4666.	0.4	8
234	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8

#	ARTICLE	IF	CITATIONS
235	Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 415-424.	1.1	7
236	<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab054.	1.4	7
237	Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2001, 949, 80-88.	1.8	6
238	Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4949-4951.	0.8	6
239	Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer-Associated Leptomeningeal Disease. <i>Clinical Breast Cancer</i> , 2012, 12, 445-449.	1.1	6
240	Does a Picture Make a Difference? Ultrasound Guidance in the Management of the Axilla After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3367-3369.	0.8	6
241	Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches. <i>Journal of Clinical Oncology</i> , 2017, 35, 2857-2859.	0.8	6
242	Examining Generalizability of Older Adults' Preferences for Discussing Cessation of Screening Colonoscopies in Older Adults with Low Health Literacy. <i>Journal of General Internal Medicine</i> , 2019, 34, 2512-2519.	1.3	6
243	Survivorship care visits in a high-risk population of breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 701-708.	1.1	6
244	CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3977-3979.	0.8	6
245	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 623-633.	1.1	6
246	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
247	Early operable breast cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 210-220.	1.3	5
248	Systemic therapy. <i>Current Opinion in Oncology</i> , 2002, 14, 600-608.	1.1	5
249	A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 33, 725-733.	1.4	5
250	Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials. <i>Breast</i> , 2013, 22, 370-373.	0.9	5
251	Systemic therapy. <i>Current Opinion in Oncology</i> , 1999, 11, 468.	1.1	5
252	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.. <i>Journal of Clinical Oncology</i> , 2014, 32, 536-536.	0.8	5

#	ARTICLE	IF	CITATIONS
253	Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates. <i>BMC Cancer</i> , 2022, 22, 141.	1.1	5
254	Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 2022, 18, 516-519.	1.4	5
255	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 391-401.	0.7	5
256	Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors. <i>Journal of Oncology Practice</i> , 2016, 12, e734-e745.	2.5	4
257	Patient-reported outcomes in the Translational Breast Cancer Research Consortium. <i>Cancer</i> , 2020, 126, 922-930.	2.0	4
258	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	1.2	4
259	Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003. , 2015, , .		4
260	TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 528-528.	0.8	4
261	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 511-511.	0.8	4
262	A method for determination of dimethyl benzoylphenyl urea(BPU) in human plasma by using LC/UV. <i>Biomedical Chromatography</i> , 2004, 18, 282-287.	0.8	3
263	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. <i>European Journal of Cancer</i> , 2007, 43, 78-86.	1.3	3
264	Reply to R. Bhargava et al and K. Lambein et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1857-1859.	0.8	3
265	Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 561-568.	1.1	3
266	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	0.8	3
267	Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. <i>Oncologist</i> , 2003, 8, 25-30.	1.9	3
268	Weight Gain after Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 4090-4103.	0.9	3
269	Adjuvant systemic management of early stage carcinoma of the breast. <i>Surgical Oncology</i> , 1999, 8, 93-101.	0.8	2
270	Systemic therapy. <i>Current Opinion in Oncology</i> , 2001, 13, 436-449.	1.1	2



#	ARTICLE	IF	CITATIONS
271	The use of anthracyclines and taxanes for adjuvant therapy of breast cancer. <i>Breast</i> , 2001, 10, 90-95.	0.9	2
272	Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 303-307.	3.4	2
273	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 828, 41-54.	1.2	2
274	Detection of circulating tumor cells in the cerebrospinal fluid: A new frontier. <i>Cell Cycle</i> , 2012, 11, 203-204.	1.3	2
275	Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 485-488.	2.5	2
276	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 520-520.	0.8	2
277	Late effects in a high-risk population of breast cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 1749-1757.	1.0	2
278	TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).. <i>Journal of Clinical Oncology</i> , 2013, 31, 515-515.	0.8	2
279	Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 647-647.	0.8	2
280	Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. , 2015, , .		2
281	DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 518-518.	0.8	2
282	Piloting survivorship care planning with the metastatic breast cancer patient.. <i>Journal of Clinical Oncology</i> , 2016, 34, 146-146.	0.8	2
283	Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. <i>Annals of Internal Medicine</i> , 2008, 149, 357.	2.0	1
284	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez). <i>Current Breast Cancer Reports</i> , 2011, 3, 1-3.	0.5	1
285	Reply to C. Murray et al and V. Martin et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3524-3525.	0.8	1
286	Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. <i>Journal of the National Cancer Institute</i> , 2022, 114, 139-148.	3.0	1
287	Making it work: Breast cancer survivorship care at Johns Hopkins.. <i>Journal of Clinical Oncology</i> , 2012, 30, 61-61.	0.8	1
288	An estimation model for Oncotype DX recurrence score using routine histopathologic variables.. <i>Journal of Clinical Oncology</i> , 2014, 32, 559-559.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 608-608.	0.8	1
290	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)â€”Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	0.8	1
291	Reply to I. Jatoi. Journal of Clinical Oncology, 2022, , JCO2200220.	0.8	1
292	New data on adjuvant therapy for breast cancer. Current Oncology Reports, 1999, 1, 31-37.	1.8	0
293	Systemic therapy. Current Opinion in Oncology, 2000, 12, 532-540.	1.1	0
294	Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications. Current Opinion in Obstetrics and Gynecology, 2003, 15, 9-12.	0.9	0
295	2014. International Journal of Radiation Oncology Biology Physics, 2006, 66, S217-S218.	0.4	0
296	The Clinical Benefit of Pegylated Liposomal Doxorubicin in Patients With Metastatic Breast Cancer Previously Treated With Conventional Anthracyclines: A Multicentre Phase II Trial. Breast Diseases, 2007, 18, 205.	0.0	0
297	Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence. International Journal of Radiation Oncology Biology Physics, 2012, 84, S219-S220.	0.4	0
298	Increased African-American Enrollment in Breast Cancer Clinical Trials: A Single-Institution Experience. International Journal of Radiation Oncology Biology Physics, 2014, 90, S597.	0.4	0
299	Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. Breast Diseases, 2015, 26, 355-358.	0.0	0
300	Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. Journal of Clinical Oncology, 2016, 34, 2203-2205.	0.8	0
301	Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer. Cancer, 2016, 122, 178-180.	2.0	0
302	Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG) Tj ETQq0 000gBT /Overlock 10	0.0	0
303	Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology, 2017, 35, 1139-1139.	0.8	0
304	In Reply. Archives of Pathology and Laboratory Medicine, 2019, 143, 413-414.	1.2	0
305	Is care coordination associated with improved care quality for comorbid conditions in cancer survivors?. Journal of Clinical Oncology, 2012, 30, 6026-6026.	0.8	0
306	TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2013, 31, 1052-1052.	0.8	0

#	ARTICLE	IF	CITATIONS
307	Webinars as a tool for breast cancer survivorship education.. Journal of Clinical Oncology, 2013, 31, 109-109.	0.8	0
308	Why is it so difficult to enroll patients in clinical trials?. Journal of Clinical Oncology, 2014, 32, 6552-6552.	0.8	0
309	A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial.. Journal of Clinical Oncology, 2014, 32, 9615-9615.	0.8	0
310	A simple, validated model for identifying cases that are unlikely to benefit from the 21-gene recurrence score (RS) assay.. Journal of Clinical Oncology, 2014, 32, 540-540.	0.8	0
311	Older adults' perspectives on incorporating life expectancy in cancer screening.. Journal of Clinical Oncology, 2016, 34, 6588-6588.	0.8	0
312	Survivorship care plans: Recommended vs delivered care.. Journal of Clinical Oncology, 2017, 35, 10076-10076.	0.8	0
313	Obesity at diagnosis and after treatment in breast cancer survivors and risk of neuropathy.. Journal of Clinical Oncology, 2018, 36, e22085-e22085.	0.8	0
314	Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer. Cancer Research, 2022, 82, P2-08-15-P2-08-15.	0.4	0